{
    "2019-09-16": [
        [
            {
                "time": "2019-09-12",
                "original_text": "【中信建投医药|行业周报】关注外资持股及CSCO大会 继续配置高性价比品种",
                "features": {
                    "keywords": [
                        "外资持股",
                        "CSCO大会",
                        "高性价比品种"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "行业延续高景气度 低估值医药股存“秋收”机会",
                "features": {
                    "keywords": [
                        "高景气度",
                        "低估值",
                        "医药股"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-09-29",
                "original_text": "29日晚公告精选|*ST大控：将触及终止上市条件，20日起停牌",
                "features": {
                    "keywords": [
                        "*ST大控",
                        "终止上市",
                        "停牌"
                    ],
                    "sentiment_score": -0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "其他"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "24批共2469个参比制剂已确定，一致性评价受理号达1722个",
                "features": {
                    "keywords": [
                        "参比制剂",
                        "一致性评价"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "【新康界评论】医药新政频发，医药行业持续景气",
                "features": {
                    "keywords": [
                        "医药新政",
                        "持续景气"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "“A+H”又添一股，曾上市连获13个涨停板",
                "features": {
                    "keywords": [
                        "A+H股",
                        "涨停板"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "其他"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "恒瑞医药：两项药品获临床试验核准 将用于治疗晚期食管癌",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "临床试验",
                        "晚期食管癌"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "光大医药 | 周报：关注医保改革新动向，继续看好创新升级",
                "features": {
                    "keywords": [
                        "医保改革",
                        "创新升级"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "恒瑞医药涉嫌接受虚开增值税普票被武汉国税局两次通报 回应称“虚开发票未流入公司”",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "虚开发票",
                        "税务问题"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "生物医药行业周报:关注创新药领域以及零售药店相关标的",
                "features": {
                    "keywords": [
                        "创新药",
                        "零售药店"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}